Skip to content

Our Pipeline

Home > Our Science > Servier’s Pipeline

RESEARCH & DEVELOPMENT

Servier’s aim is to make a difference in the lives of patients living with difficult and hard-to-treat diseases.

As a privately held company, Servier has the ability to think and invest for the long-term. Since entering the oncology space in 2018, Servier has rapidly and successfully built a powerful portfolio of precision therapeutics, and launched several new indications for IDH mutant cancers, including AML, MDS, glioma and CCA. Building on that success, Servier is expanding into neurology with the same dedication, scientific expertise and rigor that have defined its work in oncology.

Oncology

Solid Tumors
Compound / MOA
Project
Therapeutic area
Phase
Darovasertib
1st line uveal melanoma
DPC
1
2
3
Tovorafenib
Frontline RAF-altered pediatric low grade glioma
DPC
1
2
3
Ivosidenib
S95031
1st/2nd line Chondrosarcoma with IDH1 mutation
DPC
1
2
3
Vorasidenib + temozolomide
S95032
1st line Grade 4 astrocytomas
DPC
1
2
3
Ivosidenib + Durvalumab + Gemcitabine/Cisplatine​
S95031
1st line Cholangiocarcinoma with IDH1 mutation
DPC
1
2
3
Emiltatug Ledadotin (Emi-Le)
Adenoid Cystic Carcinoma, adult and pediatric solid tumors
DPC
1
2
3
DAY301
Adult and pediatric solid tumors
DPC
1
2
3
Vorasidenib + pembrolizumab
S95032
mIDH1/2 recurrent enhancing diffuse Glioma
DPC
1
2
3
Anti-TIM3 combo
S95018
Non-small cell lung cancer
DPC
1
2
3
Anti-CD73
S95024
Non-small cell lung cancer
DPC
1
2
3
Anti-NKG2A
S95029
Non-small cell lung cancer
DPC
1
2
3
Anti-NKG2A + Pembrolizumab
S95029
Gastric cancer
DPC
1
2
3
MAT2A inhibitor
S95035
Solid tumors
DPC
1
2
3
RAF/RAS clamb
S241656
Non-small cell lung cancer
DPC
1
2
3

Oncology

hematological malignancies
Compound / MOA
Project
Therapeutic area
Phase
Ivosidenib + 7 + 3 (chemo)
S95031
1st line Acute Myeloid Leukemia with an IDH1 mutation
DPC
1
2
3
Ivosidenib / Azacitidine / Venetoclax
S95031
Acute Myeloid Leukemia
DPC
1
2
3
Ivosidenib
S95031
Hypomethylating agents-naive 1st line Myelodysplastic Syndromes with IDH1 mutation
DPC
1
2
3
Cemacabtagene ansegedleucel
S95023
Diffuse Large B-Cell Lymphoma
DPC
1
2
3
BN104 menin inhibitor
S243249
R/R Acute Myeloid Leukemia and R/R Acute Lymphoblastic Leukemia with KMT2A rearrangement or NPM1 mutations
DPC
1
2
3

Neurology

Compound / MOA
Project
Therapeutic area
Phase
BK Channel Modulator
S247240
Fragile X Syndrome
DPC
1
2
3
KCNT1 ASO
S230815
Developmental Epileptic Encephalopathy
DPC
1
2
3
In Development
S233107
Rare Movement Disorder
DPC
1
2
3

These programs are investigating treatments or outcomes that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority.